SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Oldenborg, P.-A. Articles by Lindberg, F. P. Search for Related Content PubMed PubMed Citation Articles by Oldenborg, P.-A. Articles by Lindberg, F. P. Related Collections Immunobiology Red Cells Plenary Papers Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 May 2002, Vol. 99, No. 10, pp. 3500-3504 PLENARY PAPER Lethal autoimmune hemolytic anemia in CD47-deficient nonobese diabetic (NOD) mice Per-Arne Oldenborg, Hattie D. Gresham, Yongmei Chen, Shozo Izui, and Frederik P. Lindberg From the Department of Integrative Medical Biology, Section for Histology and Cell Biology, Umeå University, Umeå, Sweden; Division of Infectious Diseases, Department of Medicine and Department of Molecular Microbiology and Pathogenesis, Washington University School of Medicine, St Louis, MO; The Research Service, Albuquerque VA Medical Center and Departments of Molecular Genetics and Microbiology, University of New Mexico, Albuquerque; and Department of Pathology, University of Geneva, Geneva, Switzerland.     Abstract Top Abstract Introduction Materials and methods Results Discussion Acknowledgments References The glycoprotein CD47 (integrin-associated protein, IAP) is present on the surface of virtually all cells, including red blood cells (RBCs). CD47 acts like a marker of self by ligating the macrophage inhibitory receptor signal regulatory protein  (SIRP). In this manner mild reactivity of wild-type RBCs with macrophage phagocytic receptors is tolerated, whereas otherwise identical CD47-deficient RBCs are rapidly eliminated. We show here that virtually all CD47-deficient nonobese diabetic (NOD) mice spontaneously develop severe lethal autoimmune hemolytic anemia (AIHA) at 180 to 280 days of age, whereas none of the control CD47+ NOD mice develop lethal AIHA at least during the first year of life. This phenotype is at least partially due to a markedly increased rate of elimination of opsonized CD47/ compared to CD47+ RBCs. Similarly, CD47/C57BL/6 mice were much more sensitive than their wild-type counterparts to experimental passive AIHA induced by anti-RBC monoclonal antibodies. Thus, CD47-SIRP signaling can have a profound influence on the severity of AIHA, making manipulation of this signaling pathway a theoretically appealing avenue in the treatment of the disease. (Blood. 2002;99:3500-3504) © 2002 by The American Society of Hematology.     Introduction Top Abstract Introduction Materials and methods Results Discussion Acknowledgments References Autoimmune hemolytic anemia (AIHA) and other immune cytopenias are common in autoimmune diseases and lymphoid malignancies. AIHA is defined as an increased destruction of red blood cells (RBCs) due to the presence of anti-RBC autoantibodies.1 RBC autoantibodies are classified as warm or cold because they react optimally at temperatures between 35°C and 40°C or below 30°C, respectively.1 Warm autoantibodies are mostly IgG but may sometimes also include IgA or IgM or both.1 Binding of warm IgG autoantibodies to RBCs does not itself damage the RBCs and may or may not activate complement.1 IgG-opsonized RBCs are captured by cells of the monocyte-macrophage phagocytic system, mainly in the spleen and liver, following Fc-receptor engagement on the phagocytic cells.2-4 Treatment is immunosuppressive (cytotoxic drugs, splenectomy) or Fc receptor-competitive (IgG).5 A more complete understanding of the regulatory pathways involved in target cell recognition and elimination may provide additional and better treatment modalities. CD47 (integrin-associated protein) is a surface glycoprotein exposed on virtually all cells including RBCs.6,7 Although CD47 has been described to interact with the integrins v3, IIb3, and 21,8-11 no association with integrins has been described for CD47 on RBCs. Expression of CD47 on RBCs seems to be associated with the Rh protein complex,12 and individuals with the rare Rhnull phenotype also show profound ( 75%) reduction in the expression of CD47 on RBCs, whereas CD47 expression is normal on other cells.6 Humans with completely CD47-deficient RBCs have not been described. We have recently shown that normal RBCs are recognized by splenic macrophages and would be phagocytosed, were it not for the presence of CD47 on the RBC surface.13 This mechanism is based on the binding of CD47 on RBCs to signal regulatory protein  (SIRP) on the macrophage, which inhibits macrophage activation and phagocytosis.13 Thus, these data indicate that splenic red pulp macrophages have a phagocytic receptor(s) capable of recognizing normal circulating RBCs, and the CD47-SIRP signal is sufficient to counteract phagocytosis.13 Because the nature of this phagocytic receptor(s) is still under investigation, we refer to this functional activity as the "RBC receptor." After ligation and cross-linking, SIRP is tyrosine phosphorylated by Src family kinases at its intracellular immunoreceptor tyrosine-based inhibitory motifs (ITIMs).14 Next, these phosphorylated motifs bind the src-homology 2 domain-containing tyrosine phosphatases SHP-1 and SHP-2. Although both SHP-1 and SHP-2 seem to be present in macrophages, SHP-1 predominates.14 The importance of SHP-1 for the CD47-SIRP system is further shown by the fact that CD47-SIRP signaling is strongly reduced in motheaten viable mice,15 having a mutation resulting in reduced (about 20% of normal) SHP-1 levels but normal SHP-2 levels.16,17 Our previous data showed that CD47-SIRP signaling can also attenuate prophagocytic signals from macrophage Fc and complement receptors challenged with opsonized RBCs.15 This observation suggests that this mechanism might also be of importance in AIHA. Because it has been shown that nonobese diabetic (NOD) mice spontaneously develop mild AIHA at the age of 300 to 550 days,18 we explored the possibility that the impairment of CD47-SIRP signaling could accelerate the development and progression of AIHA in NOD mice. We show here that CD47/ NOD mice spontaneously develop severe lethal AIHA at 180 to 280 days of age, in contrast to the later development of mild anemia in CD47+ NOD mice.18 In addition, we probe the role of CD47 in the disease using transfusion experiments and a model of passive experimental AIHA.     Materials and methods Top Abstract Introduction Materials and methods Results Discussion Acknowledgments References Reagents The 5/6-carboxyfluorescein diacetate succimidyl ester (CFSE) was from Molecular Probes (Eugene, OR). The monoclonal antibody (mAb) TER-119 for detection of murine erythropoietic cells was from Pharmingen (San Diego, CA). Mouse antimouse RBC mAbs 34-3C (IgG2a) and 105-2H (IgG1), established from autoimmune-prone NZB mice,19 were purified from hybridoma supernatants by ammonium sulfate precipitation and protein A chromatography (Pharmacia, Piscataway, NJ). PKH26, secondary antibodies, and other reagents were from Sigma-Aldrich (St Louis, MO). Mice Male and female CD47/ NOD mice, back-crossed to NOD (Jackson Laboratory, Bar Harbor, ME ) for 15 generations, CD47/ C57BL/6J mice, back-crossed to C57BL/6J (Jackson Laboratory) for 16 or more generations, and their heterozygous and homozygous littermates were from our own breeding colony. Animals were kept in accordance with National Institutes of Health and local guidelines and maintained in a specific pathogen-free barrier facility. Flow cytometric detection of anti-RBC antibodies Blood (5 µL) collected during hematocrit measurements was washed twice in 1 mL phosphate-buffered saline (PBS). Surface-bound RBC autoantibodies were then detected using fluorescein isothiocyanate-conjugated F(ab')2 specific goat antimouse IgG or goat antimouse IgM antibodies. After washing off unbound secondary antibodies, the RBCs were analyzed using flow cytometry (Epics XL; Coulter, Hialeah, FL). Measurement of hematocrit and reticulocyte count Blood (70 µL) was collected into heparinized capillary tubes (Fisher Scientific, Pittsburgh, PA), from the retro-orbital vein plexa of anesthetized mice. The hematocrit tubes were spun in a hematocrit centrifuge (ICN, Needham Heights, MA), and the hematocrit was determined as the relative height of the RBC column expressed in percent.18 For reticulocyte counts, blood smears were air dried, fixed in methanol, and stained for 20 minutes in 10% modified Wright-Giemsa stain. The fraction of reticulocytes was then determined by light microscopy analysis of at least 100 RBCs/slide and expressed as percent of total RBCs.18 Experimental AIHA Studies on experimental AIHA were performed essentially as previously described.2 Weight and hematocrit were determined for recipient mice immediately before an intraperitoneal injection of 0.25, 0.5, 1, or 4 µg mAb 34-3C or mAb 105-2H/g body weight. Weight and hematocrit were determined daily. Mice showing a weight loss of more than 20% were considered moribund and killed. In vivo RBC clearance assay Clearance of CD47/ or wild-type (CD47+/+) RBCs was determined as previously described.13 RBCs were stained with the green fluorescent dye CFSE or with the red fluorescent dye PKH26 following the manufacturer's protocol and resuspended in sterile pyrogen-free 0.9% NaCl to a hematocrit of 30%. Recipients were given 200 µL of the CFSE-stained or PKH26-stained RBCs and the clearance of fluorescent RBCs was followed using flow cytometry (Epics XL, Coulter) using 5-µL blood samples collected from a tail vein at the time points indicated. The fraction of fluorescent RBCs at 30 minutes after the RBC injection was used as a reference. Control experiments showed that the choice of dye (CFSE or PKH26) did not affect clearance kinetics13,15 (not shown). Use of a 5-minute reference point gave similar results, although the experimental variation was higher this early after injection15 (not shown).     Results Top Abstract Introduction Materials and methods Results Discussion Acknowledgments References Incidence and clinical signs of AIHA in CD47/ NOD mice The NOD mice spontaneously develop mild nonlethal AIHA at the age of 300 to 550 days (up to 75% incidence in nondiabetic NOD mice at the age of 550 days).18 As part of a longitudinal diabetes study (manuscript in preparation), we followed a cohort of female CD47/ and sibling control (CD47+/+ and CD47+/) NOD mice to determine the possible effect of CD47 deficiency on development of AIHA. Mice that became diabetic well before 180 days of age were excluded from this study. The remaining mice were observed until they were 1 year old. In contrast to the mild hemolytic anemia described in old (300-550 days) wild-type NOD mice,18 the anemia in CD47/ NOD mice was severe and rapidly fatal. Virtually all CD47/ mice developed lethal anemia (hematocrit below 15%) with icterus between the ages of 180 and 280 days (Figure 1). This was neither seen in any CD47+ NOD mice (at least not until 365 days) nor in any CD47/ C57BL/6J mice. Necropsy of deceased CD47/ NOD mice showed a massively enlarged spleen (1.8 ± 0.4 g; about 10 times that normally seen in similarly aged NOD mice).20 Flow cytometric analysis revealed that a vast majority of the spleen cells of anemic CD47/ NOD mice were TER-119+ erythropoietic cells (not shown). There was also evidence of extreme erythroid expansion in vertebrae, sternum, rib tips, and long bone marrow cavities. No evidence of bleeding was seen. Thus, the severe anemia appeared to be secondary and due to a rapid destruction of RBCs. View larger version (18K): [in this window] [in a new window]   Figure 1. Nondiabetic CD47/ but not wild-type (wt) NOD mice succumb to AIHA. A cohort of CD47/ (n = 18) and wild-type (CD47+/+ or CD47+/; Wt; n = 44) NOD mice was followed for development of lethal AIHA. Survival data are shown as a Kaplan-Meier plot. All CD47/ mice in this figure developed AIHA, whereas the small loss of wild-type mice was unrelated and due to the development of diabetes. We next determined hematocrit and reticulocyte count of all the mice in the cohort at 194.4 ± 38.4 (CD47/) and 206.1 ± 43.6 (control CD47+/+ and CD47+/) days of age. Control NOD mice had normal hematocrit (47.9% ± 1.8%), whereas virtually all CD47/ mice had a reduced hematocrit (33.0% ± 10.9%; Figure 2). Peripheral blood smears from control NOD mice showed normal RBC morphology, whereas blood smears from CD47/ NOD mice were abnormal showing polychromasia and macrocytosis (not shown). As expected, there was an increased reticulocyte count (44.3% ± 33.6%) in CD47/ NOD mice, as compared with control NOD mice having a normal reticulocyte count (2.5% ± 1.5%; Figure 2). Hematocrit and reticulocyte count in CD47/ NOD mice showed a very strong inverse correlation (r = 0.99). Flow cytometric analysis showed high levels of both IgG and IgM on the RBCs of anemic CD47/ NOD mice (Figure 2). Such antibodies were not detected on RBCs from mice with normal hematocrit and reticulocyte counts. Notably, anti-RBC antibodies were not seen in any CD47+/ or CD47+/+ NOD mice at an age of 180 to 280 days (Figure 2). Thus, CD47/ NOD mice show both accelerated development of autoimmune anti-RBC antibodies and accelerated destruction of RBCs. View larger version (29K): [in this window] [in a new window]   Figure 2. Hematocrit, reticulocyte count, and relative amount of anti-RBC IgG in CD47/ and wild-type (CD47+) NOD mice. A cohort of CD47/ (n = 18) and wild-type (CD47+/+ or CD47+/; n = 44) NOD mice, at 194.4 ± 38.4 (CD47/) and 206.1 ± 43.6 (CD47+/+ and CD47+/) days of age was studied. The median hematocrit, reticulocyte counts, and anti-RBC IgG levels are indicated in the figure by a horizontal bar. The lack of CD47 on RBCs is responsible for the severity of AIHA in CD47/ NOD mice CD47/SIRP modulates Fc and complement receptor-dependent macrophage activation.15 It is therefore conceivable that the markedly accelerated development of AIHA in CD47/ NOD mice is at least in part due to the lack of CD47 on RBCs and the resulting absence of CD47/SIRP-dependent inhibitory signaling in macrophages. To test this possibility, we followed clearance of fluorescently labeled CD47/ and wild-type (CD47+/+) RBCs from healthy mice in CD47/ NOD mice with a hematocrit below 25% (Figure 3). Labeled CD47/ RBCs showed a very short half-life (1.5 hours) in the circulation of anemic CD47/ mice, whereas wild-type RBCs were not significantly cleared during the 6-hour experiment (Figure 3). Incubation of wild-type and CD47/ RBCs with serum from anemic CD47/ NOD mice resulted in identical levels of IgG and IgM deposition as assayed by flow cytometry (not shown). Thus, under otherwise identical conditions, opsonized CD47/ RBCs are much more rapidly eliminated in CD47/ NOD mice than equally opsonized wild-type cells. View larger version (22K): [in this window] [in a new window]   Figure 3. Rapid clearance of transfused CD47/ but not of transfused wild-type (CD47+/+) RBCs in CD47/ NOD mice with overt AIHA. Clearance of fluorescent-labeled RBCs from normal nonanemic CD47/ (open circles) or wild-type (CD47+/+) mice (closed circles) was followed in anemic CD47/ NOD mice with a hematocrit below 25%. Data are mean ± SD from 3 separate recipients and results were independent of the dye used to label the RBCs. Increased sensitivity to experimentally induced AIHA in CD47/ C57BL/6J mice If CD47/ mice are more sensitive to the pathogenic effect of anti-RBC antibody, this should also be apparent in models of secondary AIHA.2 Eight-week-old CD47/ or wild-type C57BL/6J mice were monitored after a single intraperitoneal injection of purified antimurine RBC mAb 34-3C (IgG2a).3,19 Compared to wild-type mice, CD47/ mice showed an extreme dose-dependent sensitivity to experimental AIHA, with a lethal outcome at doses of 1 µg mAb 34-3C/g body weight or above (Figure 4A). A dose of 4 µg/g body weight in wild-type mice was required to induce an anemia of similar severity as seen with 0.5 µg/g body weight in CD47/ mice (Figure 4A). Experiments with another antimurine RBC mAb 105-2H (IgG1), which is less pathogenic than the 34-3C mAb, but induces anemia through FcR-dependent erythrophagocytosis,3,19 confirmed the accelerated development of AIHA in CD47/ mice (Figure 4B). View larger version (27K): [in this window] [in a new window]   Figure 4. Experimental AIHA in CD47/ and wild-type (CD47+/+) C57BL/6J mice. Experimental AIHA was induced in CD47/ (open symbols) or wild-type (closed symbols) C57BL/6J mice by using (A) the antimouse RBC mAb 34-3C (mouse IgG2a), or (B) the antimouse RBC mAb 105-2H (mouse IgG1). The indicated amount of mAb 34-3C or 105-2H per gram body weight was given as an intraperitoneal injection on day 0. The mice were then followed daily for weight and hematocrit for 7 days after injection. CD47/ mice that received 1 µg mAb 34-3C/g body weight (panel A, open circles) succumbed at day 3 to 4 of the experiment. Data are mean ± SD for 3 to 4 mice in each group.     Discussion Top Abstract Introduction Materials and methods Results Discussion Acknowledgments References Our data show that the lack of the expression of CD47 promotes a markedly accelerated development of spontaneous AIHA in NOD mice and of experimental AIHA induced by 2 different anti-RBC monoclonal autoantibodies in nonautoimmune C57BL/6 mice. This indicates that the interaction of RBC CD47 with macrophage SIRP plays an important role in regulating the autoimmune elimination of opsonized RBCs in AIHA. Because CD47 is expressed on virtually all host cells, but not on foreign microorganisms, CD47-SIRP signaling is critically involved not only in prevention against autoantibody-mediated autoimmune manifestations but also in host defense against foreign antigens, by modulating the phagocytic signal mediated through the activation of Fc and complement receptors.15 Accordingly, a small degree of opsonization might suffice to trigger phagocytic activation when present on a foreign (CD47) particle, whereas a self particle, such as a CD47+ RBC, would escape phagocytosis. The latter notion is particularly significant, because this would avoid unnecessary autoimmune cellular damages by autoantibodies induced nonspecifically and transiently during microbial infections. However, sufficiently high opsonization and Fc receptor signal occurring in autoimmune diseases such as AIHA can override the CD47-SIRP signal, thereby mediating clinically overt AIHA. NOD mice, due to a specific major histocompatibility complex class II variant (I-Ag7) and a number of other interacting loci, frequently develop autoimmune destruction of pancreatic  cells and insulin-dependent diabetes.21 I-Ag7 is also associated with other autoimmune manifestations including rheumatoid arthritis and AIHA.18,22 We find that female CD47/ NOD mice develop AIHA earlier and more frequently than reported for wild-type NOD mice. The disease in CD47/ mice is almost 100% penetrant and leads to death before 1 year of age in virtually all animals. In wild-type NOD mice, AIHA is reportedly more common in diabetic than in nondiabetic mice.18 However, because a group of mice that became diabetic earlier in life was excluded from the analysis of the present study, a direct comparison of incidence is not possible. It should be stressed that anemia and anti-RBC antibodies were not found in CD47/ C57BL/6 mice, which are not predisposed to autoimmune diseases, further emphasizing a critical role of the NOD genetic background. Thus, our data indicate that the absence of CD47 by itself on RBCs is not sufficient to trigger anti-RBC autoimmune responses, but is rather implicated in the accelerated development and progression of AIHA in NOD mice. At present we do not know why CD47/ NOD mice are more prone to develop a more severe form of AIHA. Our present results, however, suggest that the effect of CD47 deficiency on AIHA in NOD mice may be 2-fold. First, CD47/ RBCs are more susceptible to autoantibody-mediated immune destruction in NOD mice, because the absent interaction between CD47 and SIRP enhances prophagocytic signals induced by Fc and complement receptors.15 Results obtained with 2 different anti-RBC monoclonal autoantibodies inducing anemia through FcR-dependent erythrophagocytosis demonstrate that CD47/ RBCs are cleared rapidly even at very low levels of opsonization in nonautoimmune C57BL/6 mice (Figure 4). This is also consistent with our previous observations that the critical factor for the accelerated clearance of opsonized RBCs is the presence or absence of CD47 on the RBCs rather than on other cells.15 Second, the absence of CD47 on RBCs may promote the spontaneous production of anti-RBC autoantibodies in mice predisposed to AIHA such as NOD mice. In fact, the analysis of in vivo opsonized RBC has demonstrated higher levels of antibody-bound RBCs in CD47/ NOD mice than in wild-type NOD mice at an age of 180 to 280 days (Figure 2), suggesting that the onset of anti-RBC autoantibody production is accelerated in CD47/ NOD mice. We do not know the mechanism underlying the accelerated production of anti-RBC autoantibodies in CD47/ versus CD47+ NOD mice. Possibly, low initial levels of anti-RBC autoantibodies, probably below the detection limit of the assay used here, are produced both in CD47/ and CD47+ NOD mice. In CD47+ NOD mice, RBCs will not be phagocytosed due to the inhibitory CD47-SIRP signaling system (Figure 5). However, in CD47/ NOD mice this mechanism will not come into play and the RBCs will be phagocytosed. This increased rate of RBC destruction may then theoretically promote antigen presentation of pathogenic self peptides, thereby creating a closed circuit that leads to accelerated generation of autoimmune anti-RBC antibodies in CD47/ NOD mice (Figure 5). Such a scenario may also explain why CD47+ NOD mice develop a less severe AIHA at a significantly older age. View larger version (21K): [in this window] [in a new window]   Figure 5. Hypothesis for a mechanism behind the accelerated development of AIHA in CD47/ NOD mice. At low levels of anti-RBC autoantibodies (1) inhibitory CD47-SIRP signaling prevents erythrophagocytosis in CD47+ NOD mice, whereas the absence of CD47-SIRP signaling in CD47/ NOD mice results in erythrophagocytosis (2).15 This may result in increased antigen presentation of self RBC peptides and sustained autoantibody production, which through increased RBC opsonization will lead to accelerated erythrophagocytosis and progressive exacerbation of AIHA in CD47/ NOD mice (3). In humans, it has long been suggested that a majority of anti-RBC autoantibodies are related to Rh.23 Therefore, based on the known association between CD47 and the Rh protein complex, it cannot be excluded that some of these autoantibodies do also interfere with CD47-SIRP interaction. Although there are today no data to support such a hypothesis, it is tempting to speculate that this can be one reason why some human anti-RBC autoantibodies are more hemolytic than others. However, this hypothesis needs further investigation. Regardless of the mechanism by which CD47 deficiency contributes to the accelerated development of AIHA, the markedly reduced clearance of CD47+ compared to CD47/ RBCs in the hemolytic anemia models suggests that enhanced SIRP signaling might be useful to decrease the severity of AIHA and possibly also of other autoimmune cytopenias. Thus, CD47 mimetics might be an alternative or complement to treatments aimed at reducing the amount of antibody, reducing the Fc receptor signal, or eliminating the clearance system.     Acknowledgments Top Abstract Introduction Materials and methods Results Discussion Acknowledgments References We thank Drs John P. Atkinson and Thomas H. Steinberg for critical evaluation of the manuscript and Eric Ford and Anna Oldenborg for excellent technical assistance.     Footnotes Submitted October 11, 2001; accepted January 7, 2002. Supported by grants from the Swedish Medical Research Council (06P-14098), the Swedish Society of Medicine, the Umeå University-Washington University exchange program, National Institutes of Health (GM57573-01), the American Diabetes Association, the Washington University-Monsanto Research Agreement, a pilot grant from the Howard Hughes Medical Institute, the Medical Research Service of the Department of Veterans Affairs, and a grant from the Swiss National Foundation for Scientific Research. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734. Reprints: Per-Arne Oldenborg, Department of Integrative Medical Biology, Section for Histology and Cell Biology, Umeå University, SE-901 87 Umeå, Sweden; e-mail: per-arne.oldenborg{at}histocel.umu.se.     References Top Abstract Introduction Materials and methods Results Discussion Acknowledgments References 1. Engelfriet CP, Overbeeke MAM, von dem Borne AEG. Autoimmune hemolytic anemia. Semin Hematol. 1992;29:3-12[Medline] [Order article via Infotrieve]. 2. Clynes R, Ravaetch JV. Cytotoxic antibodies trigger inflammation through Fc receptors. Immunity. 1995;3:21-26[CrossRef][Medline] [Order article via Infotrieve]. 3. Meyer D, Schiller C, Westermann J, et al. FcRIII (CD16)-deficient mice show IgG isotype-dependent protection to experimental autoimmune hemolytic anemia. Blood. 1998;92:3997-4002[Abstract/Free Full Text]. 4. Pottier Y, Pierard I, Barclay A, Masson PL, Coutelier J-P. The mode of action of treatment by IgG of haemolytic anaemia induced by an anti-erythrocyte monoclonal antibody. Clin Exp Immunol. 1996;106:103-107[CrossRef][Medline] [Order article via Infotrieve]. 5. Packman CH, Leddy JP. Acquired hemolytic anemia due to warm-reacting autoantibodies. In: Williams WJ,Beutler E,Erslev AJ,Lichtman MA, eds. Hematology. New York, NY: McGraw-Hill; 1990:666-675. 6. Lindberg FP, Lublin DM, Telen MJ, et al. Rh-related antigen CD47 is the signal-transducer integrin associated protein. J Biol Chem. 1994;269:1567-1570[Abstract/Free Full Text]. 7. Reinhold MI, Lindberg FP, Plas D, Reynolds S, Peters MG, Brown EJ. In vivo expression of alternatively spliced forms of integrin-associated protein (CD47). J Cell Sci. 1995;108:3419-3425[Abstract]. 8. Chung J, Gao AG, Frazier WA. Thrombospondin acts via integrin-associated protein to activate the platelet integrin IIb3. J Biol Chem. 1997;272:14740-14746[Abstract/Free Full Text]. 9. Gao AG, Lindberg FP, Dimitry JM, Brown EJ, Frazier WA. Thrombospondin modulates v3 function through integrin-associated protein. J Biol Chem. 1996;135:533-544. 10. Green JM, Zhelezniak A, Chung J, et al. Role of cholesterol in formation and function of a signaling complex involving v3, integrin associated protein (CD47), and heterotrimeric G proteins. J Cell Biol. 1999;146:673-682[Abstract/Free Full Text]. 11. Wang XQ, Frazier WA. The thrombospondin receptor CD47 modulates and associates with 21 integrin in vascular smooth muscle cells. Mol Biol Cell. 1998;9:865-874[Abstract/Free Full Text]. 12. Avent ND, Reid ME. The Rh blood group system: a review. Blood. 2000;95:375-387[Abstract/Free Full Text]. 13. Oldenborg P-A, Zheleznyak A, Fang Y-F, Lagenaur CF, Gresham HD, Lindberg FP. Role of CD47 as a marker of self on red blood cells. Science. 2000;288:2051-2054[Abstract/Free Full Text]. 14. Veillette A, Thibaudeau E, Latour S. High expression of inhibitory receptor SHPS-1 and its association with protein-tyrosine phosphatase SHP-1 in macrophages. J Biol Chem. 1998;273:22719-22728[Abstract/Free Full Text]. 15. Oldenborg P-A, Gresham HD, Lindberg FP. CD47-SIRP regulates Fc and complement receptor-mediated phagocytosis. J Exp Med. 2001;193:855-862[Abstract/Free Full Text]. 16. Kozlowski M, Mlinaric-Rascan I, Feng GS, Shen R, Pawson T, Siminovitch KA. Expression and catalytic activity of the tyrosine phosphatase PTP1C is severely impaired in motheaten and viable motheaten mice. J Exp Med. 1993;178:2157-2163[Abstract/Free Full Text]. 17. Shultz LD, Schweitzer PA, Rajan TV, et al. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell. 1993;73:1445-1454[CrossRef][Medline] [Order article via Infotrieve]. 18. Baxter AG, Mandel TE. Hemolytic anemia in non-obese diabetic mice. Eur J Immunol. 1991;21:2051-2055[Medline] [Order article via Infotrieve]. 19. Shibata T, Berney T, Reininger L, et al. Monoclonal anti-erythrocyte autoantibodies derived from NZB mice cause autoimmune hemolytic anemia by two distinct pathogenic mechanisms. Int Immunol. 1990;2:1133-1141[Abstract/Free Full Text]. 20. Crispens CG. Handbook on the Laboratory Mouse. Springfield, IL: Charles C. Thomas, Bannerstone House; 1975. 21. Atkinson MA, Leiter EH. The NOD mouse model of type 1 diabetes: as good as it gets? Nature Med. 1999;5:601-604[CrossRef][Medline] [Order article via Infotrieve]. 22. Kouskoff V, Korganow A-S, Duchatelle V, Degott C, Benoist C, Mathis D. Organ-specific disease provoked by systemic autoimmunity. Cell. 1996;87:811-822[CrossRef][Medline] [Order article via Infotrieve]. 23. Weiner W, Vos GH. Serology of acquired hemolytic anemias. Blood. 1963;22:606-613[Abstract/Free Full Text]. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: F. Guimont-Desrochers, C. Beauchamp, G. Chabot-Roy, V. Dugas, E. E. Hillhouse, J. Dusseault, G. Langlois, P. Gautier-Ethier, J. Darwiche, M. Sarfati, et al. Absence of CD47 in vivo influences thymic dendritic cell subset proportions but not negative selection of thymocytes Int. Immunol., February 1, 2009; 21(2): 167 - 177. [Abstract] [Full Text] [PDF] M. Olsson and P.-A. Oldenborg CD47 on experimentally senescent murine RBCs inhibits phagocytosis following Fc{gamma} receptor-mediated but not scavenger receptor-mediated recognition by macrophages Blood, November 15, 2008; 112(10): 4259 - 4267. [Abstract] [Full Text] [PDF] H. Bour-Jordan, B. L. Salomon, H. L. Thompson, R. Santos, A. K. Abbas, and J. A. Bluestone Constitutive Expression of B7-1 on B Cells Uncovers Autoimmunity toward the B Cell Compartment in the Nonobese Diabetic Mouse J. Immunol., July 15, 2007; 179(2): 1004 - 1012. [Abstract] [Full Text] [PDF] H. Wang, J. VerHalen, M. L. Madariaga, S. Xiang, S. Wang, P. Lan, P.-A. Oldenborg, M. Sykes, and Y.-G. Yang Attenuation of phagocytosis of xenogeneic cells by manipulating CD47 Blood, January 15, 2007; 109(2): 836 - 842. [Abstract] [Full Text] [PDF] P. P. Manna, J. Dimitry, P.-A. Oldenborg, and W. A. Frazier CD47 Augments Fas/CD95-mediated Apoptosis J. Biol. Chem., August 19, 2005; 280(33): 29637 - 29644. [Abstract] [Full Text] [PDF] M. Olsson, P. Bruhns, W. A. Frazier, J. V. Ravetch, and P.-A. Oldenborg Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia Blood, May 1, 2005; 105(9): 3577 - 3582. [Abstract] [Full Text] [PDF] G. J. Prud'homme Altering immune tolerance therapeutically: the power of negative thinking J. Leukoc. Biol., April 1, 2004; 75(4): 586 - 599. [Abstract] [Full Text] [PDF] P. P. Manna and W. A. Frazier The Mechanism of CD47-Dependent Killing of T Cells: Heterotrimeric Gi-Dependent Inhibition of Protein Kinase A J. Immunol., April 1, 2003; 170(7): 3544 - 3553. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Oldenborg, P.-A. Articles by Lindberg, F. P. Search for Related Content PubMed PubMed Citation Articles by Oldenborg, P.-A. Articles by Lindberg, F. P. Related Collections Immunobiology Red Cells Plenary Papers Social Bookmarking                   What's this?

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020